Regeneron's Libtayo cuts death risk 37% in high-risk skin cancer trial follow-up

By Public Technologies
  • Regeneron Pharmaceuticals announced longer-term Phase 3 results showing an increasing survival benefit with adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma.
  • Results presented at the ESMO 2026 Congress showed sustained benefit in preventing recurrence following surgery and radiation.
  • Survival benefits emerged despite most placebo patients receiving Libtayo upon recurrence, supporting earlier treatment.
  • Patients without detectable minimal residual disease also benefited; safety findings remained consistent with previously reported data.
  • Libtayo received US clearance in October 2025 and European Commission authorization in November 2025 as the first immunotherapy for this indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610250515PRIMZONEFULLFEED9852596) on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.